Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 6/2014

01-06-2014 | Cancer Pain (D Marcus, Section Editor)

Understanding Placebo and Nocebo Responses for Pain Management

Authors: Luana Colloca, Christian Grillon

Published in: Current Pain and Headache Reports | Issue 6/2014

Login to get access

Abstract

Placebo analgesia makes individuals experience relief of their pain simply by virtue of the anticipation of a benefit. A reduction of pain can occur also when placebos follow the administration of active and effective painkillers. In fact, studies indicate that placebos mimic the action of active treatments and promote the endogenous release of opioids in both humans and animals. Finally, social support and observational learning also lead to analgesic effects. Thus, different psychological factors and situations induce expectations of analgesia facilitating the activation of the top-down systems for pain control along with the release of endogenous mediators crucially involved in placebo-induced benefits. Recent scientific investigation in the field of brain imaging is opening new avenues to understanding the cognitive mechanisms and neurobiological substrates of expectation-induced pain modulation. Gaining deeper knowledge of top-down mechanisms of pain modulation has enormous implications for personalizing and optimizing pain management.
Literature
1.••
Colloca L, Flaten MA, Meissner K. Placebo and Pain: From bench to bedside. Oxford, UK: Elsevier; 2013. This book is the first comprehensive presentation of the placebo and nocebo phenomena in the area of pain and integrates a broad range of contributions discussing: (a) historical and methodological aspects of the placebo/nocebo effects; (b) biological and psychological mechanisms of placebo analgesia and nocebo hyperlagesia; and (c), implications of the placebo and nocebo effects for clinical research and pain management.
2.•
Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. Pain. 2013;154:511–4. This review article provides an accurate and succinct up-to-date report on current knowledge regarding the neurobiological aspects of placebo-induced modulation of pain.PubMedCentralPubMedCrossRef
3.
Colloca L, Miller FG. Role of expectations in health. Curr Opin Psychiatr. 2011;24:149–55.CrossRef
4.
5.
6.
Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211–8.PubMedCrossRef
7.
Colloca L, Tinazzi M, Recchia S, Le Pera D, Fiaschi A, Benedetti F, et al. Learning potentiates neurophysiological and behavioral placebo analgesic responses. Pain. 2008;139:306–14.
8.
Klinger R, Soost S, Flor H, Worm M. Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain. 2007;128:31–9.PubMedCrossRef
9.
Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain. 1990;43:121–8.PubMedCrossRef
10.
Fiorio M et al. Enhancing non-noxious perception: behavioural and neurophysiological correlates of a placebo-like manipulation. Neuroscience. 2012;217:96–104.PubMedCrossRef
11.
Fiorio M, Recchia S, Corra F, Tinazzi M. Behavioral and neurophysiological investigation of the influence of verbal suggestion on tactile perception. Neuroscience. 2014;258:332–9.PubMedCrossRef
12.
Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A. 2012;109:15959–64.
13.
14.
Amanzio M, Benedetti F. Neuropharmacologic dissection of placebo analgesia: expectation-activated opioid systems vs conditioning-activated specific subsystems. J Neurosci. 1999;19:484–94.PubMed
15.••
Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011;17:1228–30. This article is the first indirect pharmacologic evidence that the cannabinoid system accounts for placebo analgesic responses together with the opioid system.PubMedCrossRef
16.
Benedetti F, Pollo A, Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? J Neurosci. 2007;27:11934–9.PubMedCrossRef
17.
Guo JY, Wang JY, Luo F. Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. J Psychopharmacol. 2010;24:1561–7.PubMedCrossRef
18.
Colloca L, Benedetti F. Placebo analgesia induced by social observational learning. Pain. 2009;144:28–34.PubMedCrossRef
19.
Swider K, Babel P. The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning. Pain. 2013;154:1312–7.PubMedCrossRef
20.
21.
Vogtle E, Barke A, Kroner-Herwig B. Nocebo hyperalgesia induced by social observational learning. Pain. 2013;154:1427–33.PubMedCrossRef
22.
23.
Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt vs covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol. 2004;3:679–84.PubMedCrossRef
24.
25.
26.
Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007;147:260–71.PubMedCrossRef
27.
Bingel U, Lorenz J, Schoell E, Weiller C, Buchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006;120:8–15.PubMedCrossRef
28.
Craggs JG, Price DD, Perlstein WM, Verne GN, Robinson ME. The dynamic mechanisms of placebo induced analgesia: evidence of sustained and transient regional involvement. Pain. 2008;139:660–9.PubMedCentralPubMedCrossRef
29.
Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63:533–43.
30.
Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004;303:1162–7.
31.
Krummenacher P, Candia V, Folkers G, Schedlowski M, Schonbachler G. Prefrontal cortex modulates placebo analgesia. Pain. 2010;148:368–74.PubMedCrossRef
32.
Lui F, Colloca L, Duzzi D, Anchisi D, Benedetti F, Porro CA. Neural bases of conditioned placebo analgesia. Pain. 2010;151:816–24.
33.
Eippert F, Finsterbusch J, Bingel U, Buchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science. 2009;326:404.PubMedCrossRef
34.••
Geuter S, Buchel C. Facilitation of pain in the human spinal cord by nocebo treatment. J Neurosci. 2013;33:13784–90. his article provides evidence that nocebo manipulations leads to increased pain perception, lowered pain thresholds, and increased BOLD activity in the spinal corn. The peak activation in the ipsilateral spinal cord was at the same rostro-caudal level as shown in a twin previous study by Eippert et al (2009), in which placebo manipulations were used. Together these studies corroborate the notion that placebo and nocebo modulate pain bidirectionally at the level of the spinal cord.PubMedCrossRef
35.
Fields HL. Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res. 2000;122:245–53.PubMedCrossRef
36.
37.
38.
39.
Schweinhardt P, Seminowicz DA, Jaeger E, Duncan GH, Bushnell MC. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. J Neurosci. 2009;29:4882–7.PubMedCrossRef
40.
Kong J, Jensen K, Loiotile R, Cheetham A, Wey H-Y, Tan Y, et al. Functional connectivity of the fronto-parietal network predicts cognitive modulation of pain. Pain. 2013;154:459–67.
41.
42.•
Stein N, Sprenger C, Scholz J, Wiech K, Bingel U. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain. 2012;153:2210–7. The authors demonstrate that structural connectivity indexed by fractional anisotropy correlates with placebo analgesic responses. Positive correlations between the fractional anisotropy and individual placebo analgesic responses were found in the dorsalateral prefrontal cortex, left rostral anterior cingulate cortex, and the periacqueductal gray. The white matter integrity within and between regions of the descending pain modulatory network is crucially linked to the placebo-induced control of pain.PubMedCrossRef
43.
Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci. 2006;26:12014–22.PubMedCrossRef
44.
Kessner S, Sprenger C, Wrobel N, Wiech K, Bingel U. Effect of oxytocin on placebo analgesia: a randomized study. JAMA. 2013;310:1733–5.PubMedCrossRef
45.
46.
Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci. 2005;25:7754–62.
47.
Campbell A. Oxytocin and human social behavior. Pers Soc Psychol Rev. 2010;14:281–295.
48.
Heinrichs M, Domes G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res. 2008;170:337–50.PubMedCrossRef
49.
Hall KT, Kaptchuk TJ. Genetic biomarkers of placebo response: what could it mean for future trial design? Clin Investig. 2013;3:11–314.
50.
Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, et al. Catechol-O-Methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. 2012;7:e48135.
51.
Pecina M, et al. FAAH selectively influences placebo effects. Mol Psychiatr. 2013;19:385–91.
52.
Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004;13:2113–9.PubMedCrossRef
53.
Faria V, Appel L, Ahs F, Linnman C, Pissiota A, Frans O, et al. Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology. 2012;37:2222–32.
54.
Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci. 2008;28:13066–74.
55.
Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol. 2009;29:372–7.PubMedCrossRef
56.
Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res. 2005;58:121–7.PubMedCrossRef
57.
58.
Morton DL, Watson A, El-Deredy W, Jones AK. Reproducibility of placebo analgesia: effect of dispositional optimism. Pain. 2009;146:194–8.PubMedCrossRef
59.
De Pascalis V, Chiaradia C, Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain. 2002;96:393–402.PubMedCrossRef
60.•
Huber A, Lui F, Porro CA. Hypnotic susceptibility modulates brain activity related to experimental placebo analgesia. Pain. 2013;154:1509–18. The authors report that hypnotic susceptibility is linked to placebo analgesia from a brain imaging perspective. During the anticipatory phase, patients with higher hypnotic susceptibility showed increased anticipatory activity in a right dorsolateral prefrontal cortex and a reduction in functional connectivity within brain regions related to emotional and evaluative pain processing (anterior mid-cingulate cortex/medial prefrontal cortex). Subjects with lower hypnotic susceptibility showed an opposite pattern of fMRI activity and functional connectivity. During placebo-induced analgesia, activity in the regions reflecting attention/arousal (bilateral anterior thalamus/left caudate) and self-related processing (left precuneus and bilateral posterior temporal foci) was negatively related to analgesic placebo responses in patients with higher hypnotic susceptibility.PubMedCrossRef
61.
62.•
Pecina M, Azhar H, Love TM, Lu T, Fredrickson BL, Stohler CS, et al. Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology. 2013;38:639–46. This article outlines that some psychological traits trigger the μ-opioid-mediated placebo analgesia. Specifically, ego-resiliency, NEO Altruism, NEO Straightforwardness (positive predictors), and NEO Angry Hostility (negative predictor) traits account for 25% of the variance in the release of endogenous μ-opioids during placebo analgesia.
63.
Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol. 2007;20:435–9.PubMedCrossRef
64.
Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567–8.PubMedCrossRef
65.
Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3:70ra14.
66.
Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain. 2001;90:205–15.PubMedCrossRef
67.••
Kessner S, Wiech K, Forkmann K, Ploner M, Bingel U. The effect of treatment history on therapeutic outcome: an experimental approach. JAMA Intern Med. 2013;1–2. On days 1 and 2, either a positive or negative treatment experience was induced by combining an inert patch treatment with a conditioning manipulation. Functional magnetic resonance imaging responses were used as a physiological marker of placebo-induced analgesia. The authors found a weaker reduction of pain-related activity in the posterior insula in the negative compared with the positive treatment history group, thus, indicating the treatment history shapes behavioral and brain responses to pain experience.
68.
Colloca L, Petrovic P, Wager TD, Ingvar M, Benedetti F. How the number of learning trials affects placebo and nocebo responses. Pain. 2010;151:430–9.PubMedCentralPubMedCrossRef
69.
Andre-Obadia N, Magnin M, Garcia-Larrea L. On the importance of placebo timing in rTMS studies for pain relief. Pain. 2011;152:1233–7.PubMedCrossRef
Metadata
Title
Understanding Placebo and Nocebo Responses for Pain Management
Authors
Luana Colloca
Christian Grillon
Publication date
01-06-2014
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 6/2014
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-014-0419-2

Other articles of this Issue 6/2014

Current Pain and Headache Reports 6/2014 Go to the issue

Childhood and Adolescent Headache (S Evers, Section Editor)

Preventive Drugs in Childhood and Adolescent Migraine

Anesthetic Techniques in Pain Management (D Wang, Section Editor)

Ultrasound-Guided Stellate Ganglion Block: Safety and Efficacy

Uncommon Headache Syndromes (J Ailani, Section Editor)

It IS a Tumor- Current Review of Headache and Brain Tumor

Uncommon Headache Syndromes (J Ailani, Section Editor)

Low-Pressure/Spinal Fluid Leak Headache

Cancer Pain (D Marcus, Section Editor)

Breakthrough Cancer Pain

Cancer Pain (D Marcus, Section Editor)

Using Animal Models to Understand Cancer Pain in Humans